Adam Harris
Overview
Explore the profile of Adam Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boss M, Burdekin B, Harrison L, Rivera M, Harris A, Rout E, et al.
J Vis Exp
. 2025 Jan;
214.
PMID: 39803946
Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized...
2.
McCoy B, Mariner B, Cheng C, Slikas E, Adjangba C, Greenier A, et al.
bioRxiv
. 2024 Nov;
PMID: 39553930
Dogs exhibit striking within-species variability in lifespan, with smaller breeds often living more than twice as long as larger breeds. This longevity discrepancy also extends to health and aging-larger dogs...
3.
Mariner B, McCoy B, Greenier A, Brassington L, Slikas E, Adjangba C, et al.
bioRxiv
. 2024 Oct;
PMID: 39416178
Within a species, larger individuals often have shorter lives and higher rates of age-related disease. Despite this well-known link, we still know little about underlying age-related epigenetic differences, which could...
4.
Folz C, Seas A, Chinyengetere F, Beasley C, Harris A, Oyedeji C, et al.
J Neurosurg Case Lessons
. 2024 Jun;
7(24).
PMID: 38857545
Background: Essential tremor (ET) is one of the most common movement disorders worldwide. In medically refractory ET, deep brain stimulation (DBS) of the ventral intermediate nucleus of the thalamus is...
5.
Owens E, Harris L, Harris A, Yoshimoto J, Burnett R, Avery A
BMC Cancer
. 2024 Jan;
24(1):18.
PMID: 38166662
Background: Peripheral T-cell lymphoma (PTCL) refers to a heterogenous group of T-cell neoplasms with poor treatment responses and survival times. Canine PTCL clinically and immunophenotypically resembles the most common human...
6.
Eastwood K, Harris A, Armstrong J
CJEM
. 2023 Nov;
25(12):949-952.
PMID: 37948002
Mass-casualty incidents have a significant global impact. Despite calls for improved disaster-preparedness training, most medical curriculums do not include formal disaster-medicine education. In 2021, the Medical Council of Canada introduced...
7.
Pook D, Geynisman D, Carles J, De Braud F, Joshua A, Perez-Gracia J, et al.
Clin Cancer Res
. 2023 Jun;
29(17):3292-3300.
PMID: 37339186
Purpose: To report the safety and efficacy of ipatasertib (AKT inhibitor) combined with rucaparib (PARP inhibitor) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with second-generation androgen receptor...
8.
Matsubara N, de Bono J, Sweeney C, Chi K, Olmos D, Sandhu S, et al.
Clin Genitourin Cancer
. 2023 Jan;
21(2):230-237.e1.
PMID: 36697317
Purpose: Adding ipatasertib to abiraterone and prednisone/prednisolone significantly improved radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN-loss tumours by immunohistochemistry in the IPATential150 trial (NCT03072238)....
9.
Crowe W, Pan X, Mackle J, Harris A, Hardiman G, Elliott C, et al.
NPJ Sci Food
. 2022 Dec;
6(1):60.
PMID: 36577751
Colorectal cancer (CRC) is the second most prevelant malignancy in Europe and diet is an important modifiable risk factor. Processed meat consumption, including meats with preservative salts such as sodium...
10.
Sutaria D, Rasuo G, Harris A, Johnson R, Miles D, Gallo J, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297536
Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is...